Publications by authors named "Pascal Charef"

Claim this Profile
S
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Pascal Charef

Br J Dermatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Pascal Charef

Br J Dermatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Bardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, Isaak Effendy, Waldemar Placek, Pascal Charef

J Dermatolog Treat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects.
Jasper Dingemanse, Pascal Charef, Jed Black, Chris Gouws

Biomed Pharmacother· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Lin Cai, Jian-Zhong Zhang, Xu Yao, Jun Gu, Quan-Zhong Liu, Pascal Charef

Chin Med J (Engl)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Gerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, Bárdur Sigurgeirsson, Rong Fu, Pascal Charef

Br J Clin Pharmacol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.
Thomas Roth, Jed Black, Raymond Cluydts, Pascal Charef, Marzia Cavallaro

Sleep· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
Thomas Louie, Carl Erik Nord, George H Talbot, Mark Wilcox, Dale N Gerding, Pascal Charef

Antimicrob Agents Chemother· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis